86 related articles for article (PubMed ID: 1556050)
1. Chemotherapy for metastatic bladder cancer.
Kantoff PW; Scher HI
Hematol Oncol Clin North Am; 1992 Feb; 6(1):195-203. PubMed ID: 1556050
[TBL] [Abstract][Full Text] [Related]
2. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for muscle-infiltrating bladder cancer.
Scher HI; Kantoff PW
Hematol Oncol Clin North Am; 1992 Feb; 6(1):169-78. PubMed ID: 1556048
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
Nieuwenhuijzen JA; Bex A; Meinhardt W; Kerst JM; Schornagel JH; VAN Tinteren H; Horenblas S
J Urol; 2005 Jul; 174(1):80-5. PubMed ID: 15947583
[TBL] [Abstract][Full Text] [Related]
5. [Is neoadjuvant chemotherapy valid in invasive cancer of the bladder?].
Matveev BP; Figurin KM
Urol Nefrol (Mosk); 1998; (6):42-5. PubMed ID: 10051828
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy.
Lehmann J; Retz M; Stöckle M
World J Urol; 2002 Aug; 20(3):144-50. PubMed ID: 12196897
[TBL] [Abstract][Full Text] [Related]
7. Can patient selection for bladder preservation be based on response to chemotherapy?
Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
[TBL] [Abstract][Full Text] [Related]
8. [Current status of adjuvant chemotherapy of invasive bladder cancer].
Ozono S; Sasaki K; Watanabe S; Maruyama Y; Ohara S; Babaya K; Yamada K; Hirao Y; Okajima E
Hinyokika Kiyo; 1991 Dec; 37(12):1589-95. PubMed ID: 1785379
[TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy of metastatic cancer of the bladder. Apropos of 50 patients treated with M-VAC].
Beuzeboc P; Dhote R; Thiounn N; Flam T; Zerbib M; Debré B; Pouillart P
Cancer Radiother; 1998 Apr; 2 Suppl 1():92s-96s. PubMed ID: 9749087
[TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer].
Mikami K; Nakagawa S; Takada H; Ebisui K; Sugimoto K; Watanabe H; Maegawa M; Nakao M
Hinyokika Kiyo; 1994 Apr; 40(4):303-7. PubMed ID: 8191968
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy of invasive bladder cancer].
Kotake T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2375-82. PubMed ID: 1952956
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
Soga N; Arima K; Sugimura Y
Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review.
Sio TT; Ko J; Gudena VK; Verma N; Chaudhary UB
Int J Urol; 2014 Jul; 21(7):630-7. PubMed ID: 24455982
[TBL] [Abstract][Full Text] [Related]
14. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
Kuroda M; Kotake T
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
[TBL] [Abstract][Full Text] [Related]
15. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC].
Seguchi T; Nakano E; Miki T; Kondoh M; Nishimura K; Nakamura N; Okuyama A
Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917
[TBL] [Abstract][Full Text] [Related]
16. [Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].
Bellmunt Molins J; Ribas A; Albanell J; Lorente Garín JA; de Torres Mateos JA; Morote Robles J; López Palacios MA; Banús Gassol JM; Casado Cobo S; Eres N; Solé Calvo LA
Arch Esp Urol; 1996 Jun; 49(5):465-72. PubMed ID: 8766083
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant treatment of cancer of the bladder with M-VAC/M-VEC, and bladder-sparing policy: preliminary report of a non-randomized study.
Galante E; Ferroni C; Bianchi S; Megale C; Molinaro S; Maymone S
J Exp Ther Oncol; 1996 Jul; 1(4):237-41. PubMed ID: 9414410
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for advanced bladder cancer.
Roth BJ
Semin Oncol; 1996 Oct; 23(5):633-44. PubMed ID: 8893874
[TBL] [Abstract][Full Text] [Related]
20. [Why use chemotherapy in cancer of the bladder? What are the initial limitations].
Maraninchi D; Viens P
Ann Urol (Paris); 1994; 28(6-7):334-7. PubMed ID: 7534457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
